137 related articles for article (PubMed ID: 26861919)
1. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.
Picanço-Albuquerque CG; Morais CL; Carvalho FL; Peskoe SB; Hicks JL; Ludkovski O; Vidotto T; Fedor H; Humphreys E; Han M; Platz EA; De Marzo AM; Berman DM; Lotan TL; Squire JA
Virchows Arch; 2016 May; 468(5):607-17. PubMed ID: 26861919
[TBL] [Abstract][Full Text] [Related]
2. The Rate of Phosphatase and Tensin (PTEN) Gene Expression Loss in Prostate Cancer and its Link to Tumor Upgrading.
Gharib A; Aziminejad A; Pourmotahari F; Kazeminejad B; Soleimani M
Urol J; 2023 Dec; 20(6):403-407. PubMed ID: 36840446
[TBL] [Abstract][Full Text] [Related]
3. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.
Lotan TL; Heumann A; Rico SD; Hicks J; Lecksell K; Koop C; Sauter G; Schlomm T; Simon R
Oncotarget; 2017 Sep; 8(39):65566-65576. PubMed ID: 29029453
[No Abstract] [Full Text] [Related]
4. Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma.
Sun Z; Arnouk H
Cureus; 2023 Sep; 15(9):e45295. PubMed ID: 37846279
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization (FISH) in imprint of biopsies suspected of lymphoproliferative neoplasms: report on 17 cases.
Safranauskas RMDSO; Pasqualin DDC; Kishimoto RK; Silva MM; Oki CK; Filippi RZ; Bezerra AMPS; Velloso EDRP
Hematol Transfus Cell Ther; 2023; 45(4):516-518. PubMed ID: 36948904
[No Abstract] [Full Text] [Related]
6. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.
Moschini M; Spahn M; Mattei A; Cheville J; Karnes RJ
BMC Med; 2016 Apr; 14():67. PubMed ID: 27044421
[TBL] [Abstract][Full Text] [Related]
8. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.
Postema AW; De Reijke TM; Ukimura O; Van den Bos W; Azzouzi AR; Barret E; Baumunk D; Blana A; Bossi A; Brausi M; Coleman JA; Crouzet S; Dominguez-Escrig J; Eggener S; Ganzer R; Ghai S; Gill IS; Gupta RT; Henkel TO; Hohenfellner M; Jones JS; Kahmann F; Kastner C; Köhrmann KU; Kovacs G; Miano R; van Moorselaar RJ; Mottet N; Osorio L; Pieters BR; Polascik TJ; Rastinehad AR; Salomon G; Sanchez-Salas R; Schostak M; Sentker L; Tay KJ; Varkarakis IM; Villers A; Walz J; De la Rosette JJ
World J Urol; 2016 Oct; 34(10):1373-82. PubMed ID: 26892160
[TBL] [Abstract][Full Text] [Related]
9. Grading of Prostate Cancer: Past, Present, and Future.
Matoso A; Epstein JI
Curr Urol Rep; 2016 Mar; 17(3):25. PubMed ID: 26874537
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study.
Wu JX; Lin LM; He JY; Hong L; Li JL
Medicine (Baltimore); 2016 Feb; 95(6):e2789. PubMed ID: 26871838
[TBL] [Abstract][Full Text] [Related]
11. Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.
Schlick B; Massoner P; Lueking A; Charoentong P; Blattner M; Schaefer G; Marquart K; Theek C; Amersdorfer P; Zielinski D; Kirchner M; Trajanoski Z; Rubin MA; Müllner S; Schulz-Knappe P; Klocker H
PLoS One; 2016; 11(2):e0147739. PubMed ID: 26863016
[TBL] [Abstract][Full Text] [Related]
12. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in prostate cancer pathology: Gleason grading and beyond.
Shah RB; Zhou M
Pathol Int; 2016 May; 66(5):260-72. PubMed ID: 26991008
[TBL] [Abstract][Full Text] [Related]
14. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
Cole AI; Morgan TM; Spratt DE; Palapattu GS; He C; Tomlins SA; Weizer AZ; Feng FY; Wu A; Siddiqui J; Chinnaiyan AM; Montgomery JS; Kunju LP; Miller DC; Hollenbeck BK; Wei JT; Mehra R
J Urol; 2016 Aug; 196(2):405-11. PubMed ID: 26920466
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
17. Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study.
Thorwarth D; Notohamiprodjo M; Zips D; Müller AC
Z Med Phys; 2017 Mar; 27(1):21-30. PubMed ID: 26920460
[TBL] [Abstract][Full Text] [Related]
18. Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know.
Catalá V; Salas D; Esquena S; Mateu S; Algaba F; Palou J; de la Torre P
Actas Urol Esp; 2016; 40(6):339-52. PubMed ID: 26920095
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
